Pfizer plans to kick off an auction process for its consumer healthcare business in November, paving the way for a potential $15 billion-plus sale of the headache pill to lip balm business, sources close to the matter told Reuters.
US vascular surgeon John Martin found cancerous cells in his own neck while testing a portable ultrasound device called Butterfly iQ.
Buildups of "clumpy" proteins in the brain are well-known hallmarks of Alzheimer's, but not everyone who has them goes on to develop this neurodegenerative disease. Why is that? New research investigates.
Shire plc (LSE: SHP, NASDAQ: SHPG), the global leader in serving patients with rare diseases, announced today that the European Commission (EC) has approved a label extension granting a new indication for FIRAZYR® (icatibant injection), broadening its use to adolescents and children aged 2 years and older, with hereditary angioedema (HAE) caused by C1-esterase-inhibitor (C1-INH) deficiency. FIRAZYR has been approved in the European Union (EU) since 2008 for symptomatic treatment of acute attacks of HAE in adults with C1-INH deficiency.
The US Food and Drug Administration (FDA) has announced new measures to promote medical device innovation and provide patients with fast access to beneficial technologies.
When it comes to high blood pressure, a lack of exercise and a poor diet are often the primary suspects. A new study, however, finds that our skin may play a significant role in the development of the condition.
Biogen (NASDAQ: BIIB) announced that it has increased the profit potential on aducanumab, its Phase 3 investigational treatment for early Alzheimer’s disease, by reducing the potential royalty payment on potential commercial sales of aducanumab to Neurimmune Holding AG. In exchange for a 15 percent reduction in the previously negotiated royalty rates, Biogen agreed to make a one-time $150 million payment to Neurimmune Holding AG.
Patient participation in clinical trials for cancer patients has been in decline. Researchers determine the barriers prohibiting participation.
A drug that targets the appetite control system in the brain could bring about significant weight loss in people with clinical obesity, according to new research.
New research suggests that people with rheumatoid arthritis are more likely to develop chronic obstructive pulmonary disease (COPD), which is a group of lung diseases that damage the airways and cause problems with breathing.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.